Core Viewpoint - Pambili Natural Resources Corporation has secured C$138,500 as the first tranche of a C$1-million non-brokered private placement, aimed at supporting its operations and financial reporting requirements [1][4]. Funding Details - The first tranche consists of 2,770,000 Units, each priced at C$0.05, which includes one common share and one warrant with an exercise price of C$0.10, valid for one year [2][3]. - The total proceeds from the tranche will be allocated to various expenses, including C$90,000 for audit fees, C$15,000 for accounting fees, C$15,000 for legal fees, C$8,500 for filing fees, and C$10,000 for general and administrative costs [4]. Regulatory Context - The company is currently under a Failure to File Cease Trade Order (FFCTO) issued by the Alberta Securities Commission, and it has applied for a partial revocation to facilitate the closing of the tranche [2][4]. - The completion of the offering is contingent upon the approval from the Alberta Securities Commission and the TSX Venture Exchange [2][4]. Management Commentary - The CEO of Pambili expressed optimism regarding the company's gold projects in Zimbabwe, highlighting the potential for growth in the current high gold price environment [5].

Core Viewpoint - The Zacks Transportation - Shipping industry is facing challenges such as inflation, high interest rates, tariffs, and supply chain disruptions, but there are positive factors like a 90-day extension on tariffs against China, low oil prices, and improved demand for goods and commodities post-pandemic [1][4]. Industry Overview - The Zacks Transportation - Shipping industry is cyclical and primarily provides liquefied natural gas and crude oil marine transportation services under long-term contracts with major energy and utility companies. The industry is heavily reliant on the health of the economy, with a recovery from COVID-19 standstill benefiting its prospects [3]. Shipping Industry Trends - The extension of the tariff deadline on Chinese goods is a significant positive for the shipping industry, likely leading to a short-term increase in imports and stabilizing global trade flows [4]. - Elevated compliance costs due to regulations and rising technology-related expenses are expected to impact profits in the short term, but these investments will support long-term margins [5]. - The demand for liquefied natural gas (LNG) is increasing, particularly due to geopolitical factors, which is favorable for shipping stocks [6]. - Low oil prices are beneficial for the industry as they reduce fuel costs, which are a major expense for transportation companies. Oil prices have declined by 6% in the April-June period, benefiting oil tanker companies [7]. Industry Performance - The Zacks Transportation - Shipping industry has underperformed compared to the S&P 500 index, declining by 20.2% over the past year, while the S&P 500 increased by 16% [11]. - The industry currently has a Zacks Industry Rank of 98, placing it in the top 40% of 246 Zacks industries, indicating positive near-term prospects [9]. Valuation - The industry is trading at a forward price-to-earnings (P/E) ratio of 6.82X, significantly lower than the S&P 500's 22.86X and the sector's 14.36X [14]. Stock Recommendations - Dorian LPG has seen a stock increase of 56% over the past six months, driven by rising demand for liquefied petroleum gases [16]. - Euroseas has gained 41% over the past year, benefiting from profitable contracts and a time charter equivalent rate exceeding $30,000 per day [20]. - Ardmore Shipping's stock has increased by 18% over the past six months, with a focus on product and chemical tankers [23].

Group 1: Ardmore Shipping (ASC) - Ardmore Shipping is engaged in the ownership and operation of product and chemical tankers, carrying a Zacks Rank 1 (Strong Buy) [1] - The Zacks Consensus Estimate for Ardmore Shipping's current year earnings has increased by 2.6% over the last 60 days [1] - The company has a price-to-earnings ratio (P/E) of 9.15, significantly lower than the industry average of 19.5, and possesses a Value Score of A [2] Group 2: Dillard's (DDS) - Dillard's is a large departmental store chain featuring fashion apparel and home furnishings, also carrying a Zacks Rank 1 [2] - The Zacks Consensus Estimate for Dillard's current year earnings has increased by 2.6% over the last 60 days [2] - Dillard's has a price-to-earnings ratio (P/E) of 16.25, which is lower than the industry average of 19.80, and possesses a Value Score of A [3] Group 3: Healthcare Services Group (HCSG) - Healthcare Services Group provides housekeeping, laundry, linen, facility maintenance, and food services to the healthcare industry, including nursing homes and hospitals, and carries a Zacks Rank 1 [4] - The Zacks Consensus Estimate for Healthcare Services Group's current year earnings has increased by 4.8% over the last 60 days [4] - The company has a price-to-earnings ratio (P/E) of 17.31, compared to the industry average of 21.10, and possesses a Value Score of A [5]

Investors should also recognize that ASC has a P/B ratio of 0.69. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. ASC's current P/B looks attractive when compared to its industry's average P/B of 1.40. Over the past year, ASC's P/B has been as high as 1.32 and as low as 0.57, with a median of 0.74. Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. This ...

Core Insights - Ascletis Pharma Inc. announced promising preclinical efficacy results for ASC47, a first-in-class muscle-preserving weight loss drug candidate, in combination with ASC31, a dual-targeting peptide agonist for GLP-1R and GIPR [2][6] Group 1: Drug Candidates - ASC47 is an adipose-targeted, once-monthly subcutaneously injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, developed in-house at Ascletis, which shows high drug concentrations in adipose tissue [4] - ASC31 is a novel peptide agonist targeting both GLP-1R and GIPR, demonstrating a favorable pharmacokinetic profile and promising efficacy in diet-induced obese (DIO) mice [3][5] Group 2: Efficacy Results - In a DIO mouse model, the combination of a low dose of ASC47 (9 mg/kg, SQ) with ASC31 (3 nmol/kg, SQ) resulted in a 44.8% reduction in body weight after 14 days, compared to a 38.1% reduction with ASC47 combined with tirzepatide [1][5] - The combination of ASC47 with ASC31 was found to be 17.6% more effective than the combination with tirzepatide, with statistical significance (p=0.02) [5] Group 3: Company Overview - Ascletis Pharma Inc. is focused on developing and commercializing potential best-in-class and first-in-class therapeutics for metabolic diseases, utilizing proprietary platforms for drug discovery [7]

Core Viewpoint - Ardmore Shipping (ASC) shows potential for upside with a mean price target of $13.17, indicating a 25.6% increase from the current price of $10.49 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $0.76, suggesting variability in analyst predictions [2] - The lowest estimate of $12.50 indicates a 19.2% increase, while the highest estimate of $14.00 suggests a 33.5% increase [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding ASC's earnings prospects supports the expectation of stock upside [4][11] - The Zacks Consensus Estimate for the current year has increased by 2.6% over the past month, with one estimate rising and no negative revisions [12] - ASC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a directional guide for potential price movements [14]

Core Viewpoint - Ardmore Shipping (ASC) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, suggesting that upward revisions in earnings estimates can lead to higher stock prices [4][6]. - Ardmore Shipping is projected to earn $1.20 per share for the fiscal year ending December 2025, with no year-over-year change, but the Zacks Consensus Estimate has increased by 2.6% over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, indicating superior earnings estimate revisions, which positions Ardmore Shipping favorably for potential market-beating returns [9][10].

| Source:Ascencio SA Interim statement at 30 June 2025 Ascencio Interim statement at 30.06.2025 Rental income : €40.6 million, up by 1.8% from €39.9 million at 30/06/2024 EPRA Earnings : €28.5 million, up by 2.1% from €27.9 million at 30/06/2024 EPRA Earnings per share : €4.32 (vs €4.23 at 30/06/2024) Net result : €26.4 million (vs €21.0 million at 30/06/2024) Fair value of the property portfolio : €745.2 million (vs €748.6 million at 30/09/2024) Debt ratio (EPRA LTV) : 41.8%, down from 42.1% at 30/09/2024 ...

Core Insights - Ascletis Pharma Inc. announced promising efficacy results from a study combining ASC47, a muscle-preserving weight loss drug candidate, with tirzepatide in diet-induced obese (DIO) mice [3][9] Group 1: Efficacy Results - The combination of ASC47 low dose with tirzepatide resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy, with average total body weight reductions of 38.1% versus 20.4% respectively [1][5] - ASC47 low dose combined with tirzepatide demonstrated a statistically significant increase in efficacy compared to ASC47 low dose combined with semaglutide, achieving 87% weight loss versus 55% [1][5] Group 2: Body Composition Restoration - The combination therapy restored the body composition of obese mice to levels similar to healthy non-obese mice, with total muscle mass percentages of 60.4% for the combination group compared to 62.0% for healthy controls [2][8] - Tirzepatide monotherapy did not restore body composition to healthy levels, indicating the potential superiority of the ASC47 and tirzepatide combination [8] Group 3: Drug Properties - ASC47 is a first-in-class, adipose-targeted, once-monthly subcutaneously injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, developed in-house by Ascletis [4] - The drug's unique properties allow for high drug concentrations in adipose tissue, which may contribute to its efficacy in weight loss [4]

In a sector often dismissed as volatile and un-investable, Ardmore Shipping (NYSE: ASC ) is quietly building a case for itself as a capital-efficient and a well-run outlier in the refined products and chemical tanker space. After digging into its latest results My investing approach blends macroeconomic analysis with valuation models, including DCF, multiple-based analysis. I pay close attention to financial structure, free cash flow generation, and capital allocation discipline. I'm particularly drawn to c ...